Hogan Lovells welcomes back Xin Tao to the firm’s Pharmaceutical and Biotechnology group, deepening global reach

Xin brings nearly 15 years of experience advising life sciences, food, consumer platform, and technology companies and investors on global compliance and transactions, particularly those headquartered in China or expanding their business across the Asia-Pacific region. As a former research scientist, Xin draws on his experience to provide clients with practical advice on complex regulatory matters affecting the life sciences and technology industries. His practice spans pharmaceutical, medical device, food, cosmetics, and consumer technology.

“We are thrilled to welcome Xin back to Hogan Lovells,” said Janice Hogan, Practice Group Leader – Global Regulatory & IP. “As the world operates in an environment characterized by heightened regulatory scrutiny and increasing geopolitical sensitivity, his arrival reinforces our commitment to expanding our high-stakes compliance work across the life sciences sector with an emphasis on global market entry, including from China.”

With a deep understanding of U.S. and EU regulatory systems alongside Asian business environments, Xin helps clients navigate the legal, commercial, and cultural dimensions of cross-border collaborations and strategic transactions. He has represented many international companies in high-stakes U.S. government investigations, including proceedings involving the U.S. Congress, the U.S. Department of Justice, the U.S. Food and Drug Administration, the Federal Trade Commission, and the U.S. Consumer Product Safety Commission concerning product safety, regulatory compliance, and national security issues.

“Xin’s return comes at the perfect time,” said David Fox, Practice Area Leader – Pharmaceuticals and Biotechnology. “His experience guiding Chinese companies pursuing global expansion through the unique regulatory challenges they face is a complement to our existing work and will aid our clients immensely.”

“In the wake of our successful vote to become Hogan Lovells Cadwalader, Xin will be a true asset in deepening our regulatory offering in D.C. for global companies seeking to do business in the United States,” said Ajay Kuntamukkala, Office Managing Partner – Washington, D.C. “His familiarity with how Washington works will help our clients as they seek to navigate ever shifting regulations.”

Xin added: “I am excited to return to Hogan Lovells and practice alongside this outstanding group of lawyers. Having previously spent more than nine years at the firm, I have long valued its fully integrated and well-balanced global platform, collaborative culture, and deep regulatory capabilities. With exceptional strength across the world’s major economies, including a deep bench across the G20, and partners across jurisdictions who understand and appreciate the needs of Chinese and other international clients, the firm provides an exceptional platform for supporting our clients as they navigate complex cross-border challenges in pursuit of innovation and global growth amid an increasingly uncertain regulatory environment.”

Xin received his J.D. from Georgetown University Law Center, his M.S. in Biochemistry from Texas A&M University, and his B.S. in Biochemistry from Shanghai Jiaotong University.

About the Hogan Lovells Washington, D.C. office

Since 1904, our lawyers in the nation's capital have been instrumental in assisting clients in resolving their most difficult commercial, regulatory, and legal obstacles. Hogan Lovells' Washington, D.C. office is the firm's largest office in the United States, with over 500 lawyers spanning all three of the firm's practice groups -- Corporate & Finance, Global Regulatory and IP, and Litigation, Arbitration and Employment. We operate at the intersection of business and government, with a deep understanding of how geopolitics, political risks, and regulatory issues affect clients across numerous sectors.